Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC). In all, 84 patients with recurrent or metastatic CRC with measurable disease were included. Treatment consisted of oxaliplatin 85 mg m(-2) in 120-min intravenous (i.v.) infusion on days 1 and 15; i.v. l,leucovorin (l,LV) 250 mg m(-2) given in 2 h on day 1, followed by oral UFT 390 mg m(-2) on days 1-14, and oral l,LV 7.5 mg/12 h on days 2-14. Cycles were repeated every 28 days. A total of 492 cycles of chemotherapy were delivered with a median of six per patient (range 1-12). There was one complete response (1%) and 28 partial responses (34%) for an overall response rate of 35% (95% confidence interval (CI): 24-46%). A total of 36 patients (44%) had stable disease, whereas 17 (21%) had a progression. The median time to progression was 7.3 months and the median overall survival was 16.8 months. A prescheduled preliminary analysis was performed after inclusion of 16 patients who detected a high gastrointestinal toxicity, which led to a reduction of the UFT dose to 300 mg m(-2). With this new dosage, grade 3-4 diarrhoea and grade 3-4 nausea/vomiting dropped to 21 and 14% of patients, respectively. Other grade 3-4 toxicities were stomatitis in one (1%), anaemia in three (5%), neutropenia in two (3%), thrombocytopenia in one(1%), fatigue in six (9%), peripheral sensory neuropathy in nine (14%) and laryngopharyngeal dysesthesia in two patients (2%). The combination of oxaliplatin and UFT-l,LV is an active, easy-to-administer regimen with moderate toxicity. Hence, this regimen is worthy of further investigation.
 ...
PMID:Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. 1550 21

In lung cancer patients, chemotherapy-induced complications are considered to be distressing reactions even in the era of new antiemetics, such as aprepitant. The aim of this study was to evaluate the incidence of such complications. This prospective observational study was performed in our institution between 2011 and 2012. Certain complications including nausea, vomiting, appetite, stomatitis, constipation, diarrhea and dysesthesia, on days 1-7 were evaluated by pharmacists. The questionnaires and diaries of chemotherapy-induced complications were evaluated in the 31 patients included in the study. The majority of the enrolled patients were male (81%). Six (19%) patients were administered cis-diamminedichloroplatinum(II) (CDDP)-, 21 (69%) chemotherapy by carboplatin (CBDCA)- and 4 (13%) non-platinum regimen chemotherapies. Ten (32.3%) of the 31 patients exhibited nausea but only 3 (9.7%) of them experienced vomiting. On days 5-6, 23.8 and 9.5%, respectively, of patients treated with CDDP-regimens had nausea and vomiting. Three of the other most common complications were constipation, general fatigue and appetite loss. The incidence of these complications was 77.4, 71.0 and 67.7%, respectively. Even in the era of new antiemetics, CDDP-regimen chemotherapy-induced nausea and vomiting as well as constipation; general fatigue and appetite loss continue to be problems. A better appreciation of the incidence of these chemotherapy-related complications by medical oncologists and medical staff is essential for their adequate control.
 ...
PMID:Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists. 2464 24